A Phase 0 Study to Evaluate the Pharmacokinetics of Low-dose Bevacizumab and Its Efficacy on Reducing Plasma Free Vascular Endothelial Growth Factor-A (VEGF-A) in Hemodialysis Patients
Latest Information Update: 06 Nov 2021
Price :
$35 *
At a glance
- Drugs Bevacizumab (Primary)
- Indications Renal failure
- Focus Pharmacodynamics; Pharmacokinetics
- 06 Jul 2020 Planned initiation date changed from 1 Apr 2016 to 1 Aug 2019.
- 06 Jul 2020 Status changed from recruiting to withdrawn prior to enrolment.
- 09 Apr 2019 Planned End Date changed from 1 Nov 2016 to 1 Nov 2021.